Acute myelomonocytic leukaemia
Acute myelomonocytic leukaemia (AMML) is a rare, fast-growing blood cancer. Find out what AMML is, the signs and symptoms, and how it is diagnosed and treated.
Download our factsheet about AMML
Summary
- AMML is a rare, fast-growing blood cancer.
- We do not know the exact cause of AMML, but it not because of anything you have or have not done.
- AMML is usually diagnosed from blood tests and bone marrow tests.
- You might have intensive or non-intensive treatment for AMML. Your team will tell you what they recommend for you.
- Intensive treatment aims to get AMML into remission.
- Non-intensive treatment is gentler. It aims to control AMML as much as possible rather than cure it.
- It can be hard dealing with side effects and treatment. Ask your friends, family, medical team or Leukaemia Care if you need support.
About AMML
AMML is a fast-growing blood cancer. It is a rare type of acute myeloid leukaemia (AML).
AMML develops when immature white blood cells called myeloblasts and monocytes divide uncontrollably. They build up in your bone marrow and stop it making enough healthy blood cells.
We do not know the exact cause of AMML, but it is not because of anything you have or have not done.
Signs and symptoms of AMML
The signs and symptoms of AMML include:
- Fatigue
- Fever
- Infections
- Feeling breathless
- Low red blood cell count (anaemia)
- Bruising or bleeding
- A swollen spleen or liver
- Swollen lymph nodes
AMML is usually diagnosed from blood tests and bone marrow tests.
Treating AMML
Treatment options for AMML are similar to those used for other types of AML.
Your haematology team will recommend either intensive or non-intensive treatment, depending on your individual needs.
Your team will explain what treatment they recommend and what you can expect from treatment.
We have separate information on different treatments.
Intensive treatment happens in phases.
- Induction phase
- Aims to kill as many leukaemia cells as possible.
- Usually involves chemotherapy, sometimes with a targeted medicine.
- You usually stay in hospital for a few weeks to have it.
- Consolidation phase
- Aims to kill any leukaemia cells that may be left.
- Often involves cycles of chemotherapy, sometimes with a targeted medicine. Some people might have a stem cell transplant.
- You usually have it in hospital and go home between cycles.
- Maintenance phase
- Aims to reduce the risk of your AMML coming back.
- Usually involves tablets to take at home.
Non-intensive treatment is gentler. It aims to control your AMML as much as possible rather than cure it. It usually involves low-dose chemotherapy or targeted therapy to take at home.
The outcome of AMML varies from person to person. Your medical team are best placed to discuss what they expect for you.
It can be hard dealing with treatment and its side effects. Don’t be afraid to ask for help from family, friends, your medical team or Leukaemia Care.
Downloads or relevant links
AMML is a subtype of acute myeloid leukaemia (AML). We have more information on:
- About AML
- Gene changes in AML
- Treatment for AML – this includes many options used to treat AMML
- Relapsed or refractory AML
- Stem cell transplants
We also have lots of AML resources to download, or free booklets about AML to order in print.
Need support?
We are dedicated to ensuring that anyone affected by leukaemia receives the best possible diagnosis, information, advice, treatment and support.
If you need support with any aspect of your or a loved one’s diagnosis:
- Call our free helpline on 08088 010 444 or send a WhatsApp message to 07500 068 065 (services available Monday to Friday, 9am to 5pm)
- Visit our support page to find out about our other services, including support groups, a one-to-one buddy, financial support or counselling
Help us improve our information
We aim to provide information that’s reliable, up-to-date, and covers what matters to you. We want you to feel supported and able to be involved in decisions about your care. Please complete our short survey to help us improve our information and make sure it meets your needs.
If you have any feedback on our information, or you’d like a list of the references we used to develop it, please email information@leukaemiacare.org.uk
Review date
Last updated: March 2025
Review date: March 2028